MAZE

Maze Therapeutics, Inc. (NASDAQ:MAZE) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in South San Francisco, California. Originally incorporated as Modulus Therapeutics, Inc., the company changed its name to Maze Therapeutics in September 2018. The company went public on January 31, 2025, representing one of the first biotechnology IPOs of the year. Maze focuses on developing precision medicines for serious diseases affecting the kidneys, cardiovascular system, and related metabolic conditions, with a particular emphasis on genetic-based therapeutic approaches.